focus -WSS

focus

author：fashion 2025-09-30 11:27:46 - browse：5

The FDA building -- First Opinion coverage from STAT — Adobe

The clearance of a first-of-its-kind cancer treatment made by Amgen is on shakier ground following a Food and Drug Administration advisory committee meeting Thursday.

Regulatory advisers voted 10-2 that the data on the company’s drug Lumakras, a treatment for lung cancer, could not be properly assessed. Lumakras targets a specific mutation to a protein called KRAS, which is one of the most common genetic mutations in cancer.

The vote comes as Amgen is hoping to convert a conditional approval for the drug to a full approval based on a 345-person study called CodeBreaK 200, in which Lumakras met the primary endpoint, delaying tumor growth approximately five weeks longer than the standard of care medication, docetaxel. The drug didn’t extend patients’ overall survival.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Supreme Court strikes down Biden student loan forgiveness program

WSS

Wildfire smoke map: Which US cities are forecast to be impacted by fires burning in Canada

Prince Harry seeks over $550,000 in phone hacking lawsuit against British tabloid publisher

Eli Lilly, Pfizer, and others want in on the online prescription market

NIH director takes cautious approach to Biden drug pricing priority

Illumina to lay off 10% of research and development team

New lesbian bars spark hope amid disappearing LGBTQ+ spaces

explore

focus

hotspot

Virginia high school admissions case could be legal follow

Why do we get seasonal allergies?

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Tuskegee Airman Raymond Cassagnol dies at 102

United colonoscopy coverage change 'may cost lives,' doctors say

UnitedHealth wins $3.3 billion takeover of Amedisys

Cancer drug shortages should be causing more outrage

Independent physicians launch a new lobbying group

Tori Bowie and the unacceptable rates of Black maternal death

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

knowledge

Readout Newsletter: Merck, J&J, and long Covid

Research misconduct: Proposed new rules face resistance

The surgeon had a dilemma only a Nazi medical text could resolve

Brazil's Jair Bolsonaro is barred from running for office until 2030

What Wagner Group's armed rebellion could mean for Russia's endgame in Ukraine

The simple reason for the increase in autism diagnosis

Wikipedia

focus

focus

leisure time